Angiogenesis is crucial for hepatocellular carcinoma (HCC) development. This study found that sphingosine-1-phosphate receptor 1 (S1PR1) is highly expressed in HCC blood vessels and promotes HCC angiogenesis and progression in vitro and in vivo. Mechanistically, HCC-derived proangiogenic factors (S1P, IL-6, VEGFA) upregulate S1PR1 in endothelial cells (ECs) via STAT3 phosphorylation. S1PR1 decreases ceramide levels by downregulating CerS3 through CerS6 nuclear translocation. Lenvatinib significantly downregulates S1PR1, enhancing angiogenesis inhibition. Therefore, S1PR1 is a promising therapeutic target for HCC.